Fetal hydrocephalus is a relatively common prenatal diagnosis associated with perinatal mortality and long-term neurodevelopmental impairment. Studies of its natural history and of prenatal and postnatal treatments report heterogeneous outcomes, defined and measured in different ways and at different time points, which prevents comparison between studies and evidence synthesis. No core outcome set (COS) exists for this condition. This project aims to develop a COS for studies of prenatally diagnosed fetal hydrocephalus, including trials of prenatal intervention, incorporating the views of parents, people living with hydrocephalus, healthcare professionals and researchers, following the COMET Handbook and COS-STAD recommendations.
ContributorsPrincipal investigator: Alireza A. Shamshirsaz – Comprehensive Fetal Care Center, Dell Children's Medical Center; Division of Fetal Medicine and Therapy, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
Disease Category: Pregnancy & childbirth
Disease Name: Fetal hydrocephalus (prenatally diagnosed severe ventriculomegaly)
Age Range: 0 - 10
Sex: Either
Nature of Intervention: Any
- Clinical experts
- Consumers (caregivers)
- Consumers (patients)
- Families
- Researchers
- COS for clinical trials or clinical research
- COS for practice
- Consensus meeting
- Delphi process
- Interview
- Literature review
- Survey
- Systematic review
(1) Systematic review of outcomes reported in studies of prenatally diagnosed fetal ventriculomegaly or hydrocephalus (ongoing; PROSPERO CRD420261517158).
(2) Semi-structured interviews with parents/caregivers and adults living with congenital hydrocephalus to identify additional outcomes; the steering committee will merge, classify (COMET outcome taxonomy) and finalize the long list, with plain-language descriptions and a pilot of the questionnaire.
(3) Three-round international online Delphi survey with three stakeholder panels: (A) parents, caregivers and people with lived experience; (B) professionals in prenatal care and fetal therapy; (C) professionals in neonatal, neurosurgical, neurological and long-term care. Outcomes scored on the GRADE 9-point scale, with feedback by panel between rounds. Consensus in: =70% scoring 7–9 and <15% scoring 1–3 in every panel. Target =120 participants in round 1 (=40 per panel).
(4) Consensus meeting using a modified nominal group technique with anonymous voting to agree the final COS and outcome definitions.
Selection of outcome measurement instruments will follow in a separate step (COSMIN–COMET guideline).